Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA to review MRI (magnetic resonance imaging) data analysis software:

This article was originally published in Clinica

Executive Summary

Confirma says that the US FDA has accepted for review the second of a five-module PMA application for its software product that analyses MRI data to improve a doctor's ability to stage cancer patients. The ACCENT software analyses MRI data to provide information about the size and locations of cancerous tumours throughout the body. It is currently being tested in a clinical trial involving breast and prostate cancer patients, reports the Kirkland, Washington company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069874

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel